While the Parkinson’s disease market is set to expand from $2.1 billion in 2014 to $3.2 billion by 2021, at a moderate compound annual growth rate (CAGR) of 5.7%, game-changing treatments will not be available for the foreseeable future, a new study suggests. 26 February 2016
Australia’s Parliament has today passed the Turnbull Government’s historic legislation delivering the “missing piece” for Australian patients and their doctors to access a safe, legal and reliable supply of medicinal cannabis products for the management of painful and chronic conditions. 24 February 2016
Seven of the world’s largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s. 23 February 2016
Swiss drugmaker Primex Pharmaceuticals has signed a deal with France-based Advicenne to acquire global rights for the latter’s lead product, an advanced oral pharmaceutical candidate for pediatric anesthesiology. The market potential is evaluated as “hundreds of millions of euros.” 23 February 2016
The US Food and Drug Administration yesterday approved Briviact (brivaracetam), from Belgium’s UCB, as an add-on treatment to other medications to treat partial onset seizures in patients aged 16 years and older with epilepsy. 20 February 2016
The treatment market for bipolar disorder is set to decrease from $5.8 billion in 2014 to $4.2 billion by 2024, at a negative compound annual growth rate (CAGR) of 3.2%, as generic erosion continues to deter the development of novel therapies, according to a new study. 19 February 2016
NLS Pharma has announced the acquisition of four patents including one linked to an innovative compound the company seeks to develop for the treatment of attention-deficit hyperactivity disorder (ADHD). 18 February 2016
The US Food and Drug Administration has granted Breakthrough Therapy Designation for Roche’s investigational medicine Ocrevus (ocrelizumab) in primary progressive multiple sclerosis (PPMS). 17 February 2016
Canada’s Minister of Health Jane Philpott has announced funding for research aimed at improving the health of people who abuse prescription drugs. 17 February 2016
UK drug discovery firm e-Therapeutics yesterday reported disappointing top-line results for its Phase IIb trial of ETS6103 in major depressive disorder, evaluating its antidepressant activity and tolerance profile, showing the drug was less effective than tricyclic alternatives. 16 February 2016
Scientists from Charles River Laboratories are to work at Eisai's research and development facilities in the UK under a new collaboration agreement. 15 February 2016
Japan’s Shionogi has submitted a New Drug Application for the manufacturing and marketing in Japan of S-877503 (guanfacine hydrochloride prolonged release tablets; marketed in the USA as Intuniv), for the treatment of attention-deficit hyperactivity disorder (ADHD) in children. 12 February 2016
The UK’s Competition and Markets Authority announced this morning that it has fined a number of pharmaceutical companies for anti-competitive conduct and agreements relating to the supply of the antidepressant drug paroxetine. 12 February 2016
Teva Pharmaceutical Industries, the world’s largest generics maker, has reported a decline in fourth quarter profits as sales of its best-selling drug face competition. 11 February 2016
In response to the opioid abuse epidemic in the USA, yesterday Robert Califf, the US Food and Drug Administration’s Deputy Commissioner for Medical Products and Tobacco, along with other FDA leaders, called for a far-reaching action plan to reassess the agency’s approach to opioid medications. 5 February 2016
The US Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee (PDAC) voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD). 4 February 2016
Japanese drug major Eisai has entered into a new agreement with Spain’s Esteve to co-promote Fycompa (perampanel) in Spain from February 2016. No financial details of the accord were disclosed. 4 February 2016
Danish CNS specialist Lundbeck and Otsuka Pharmaceutical Europe on Wednesday said the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for a label update of Abilify Maintena (aripiprazole) to describe new clinical data for the treatment of acutely relapsed adults with schizophrenia. 3 February 2016
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024